Coventry B J, Lee P-L, Gibbs D, Hart D N J
Department of Surgery, University of Adelaide, Royal Adelaide Hospital, North Terrace, Adelaide, South Australia 5000, Australia.
Br J Cancer. 2002 Feb 12;86(4):546-51. doi: 10.1038/sj.bjc.6600132.
Low CD1a-positive putative dendritic cell numbers in human breast cancer has recently been described and may explain the apparent 'poor immunogenicity' previously reported in breast cancer. Little attention has been given to dendritic cell activation within the tumour microenvironment, which is another reason why the in-situ immune response may be severely deficient. We have therefore examined CD1a expression as a marker for dendritic cells, together with CMRF-44 and -56 as markers of dendritic cell activation status, in 40 human breast cancers. The results demonstrate few or no CD1a-positive putative dendritic cells and minimal or no expression of the dendritic cell activation markers. Both dendritic cell number and dendritic cell activation appear substantially deficient in human breast cancers, regardless of tumour histological grade.
最近有研究报道,人类乳腺癌中CD1a阳性的假定树突状细胞数量较少,这可能解释了先前报道的乳腺癌明显的“免疫原性差”现象。肿瘤微环境中的树突状细胞激活很少受到关注,这也是原位免疫反应可能严重不足的另一个原因。因此,我们检测了40例人类乳腺癌中作为树突状细胞标志物的CD1a表达,以及作为树突状细胞激活状态标志物的CMRF-44和-56。结果显示,CD1a阳性的假定树突状细胞很少或没有,树突状细胞激活标志物的表达也极少或没有。无论肿瘤组织学分级如何,人类乳腺癌中的树突状细胞数量和树突状细胞激活似乎都严重不足。